Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

@article{Milutinovic2016DualAS,
  title={Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.},
  author={Snezana Milutinovic and Arun Kumar Kashyap and Teruki Yanagi and Carina Wimer and Sihong Zhou and Ryann O'Neil and Aaron L. Kurtzman and Alexsandr Faynboym and Li Xu and Charles H. Hannum and Paul W. Diaz and Shu-ichi Matsuzawa and Michael Abel Horowitz and Lawrence Horowitz and Ramesh R. Bhatt and John C. Reed},
  journal={Molecular cancer therapeutics},
  year={2016},
  volume={15 1},
  pages={114-24}
}
Death receptors of the TNF family are found on the surface of most cancer cells and their activation typically kills cancer cells through the stimulation of the extrinsic apoptotic pathway. The endogenous ligand for death receptors 4 and 5 (DR4 and DR5) is TNF-related apoptosis-inducing ligand, TRAIL (Apo2L). As most untransformed cells are not susceptible to TRAIL-induced apoptosis, death receptor activators have emerged as promising cancer therapeutic agents. One strategy to stimulate death… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

LA.Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection

  • XiangH, Reyes AE2nd, S Eppler, S Kelley, Damico-Beyer
  • Cancer Chemother Pharmacol
  • 2013

Similar Papers

Loading similar papers…